DUBLIN, June 27, 2022 /PRNewswire/ -- The "Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive insight on clinical and non-clinical factors that are driving the global CFTR Modulators market and its impact on the global pharmaceutical market landscape.
The encouraging response of CFTR modulators in the market has led to further research and development activities in this domain. Several promising compounds are currently being evaluated which can be proven to be alternatives to VX-770 to overcome gating mutations. Vertex pharmaceutical is conducting a clinical trial on VX-561 (also called deutivacaftor) an analog of VX-770 in which one of the tert-butyl groups was replaced by a per-deuterated one. The preclinical data have demonstrated that the drug has similar activity as VX-770; however, it has enhanced stability suggesting it could be prescribed once daily only, contrary to VX-770, which must be administered every 12 hours. The company is also developing another corrector, VX-121, which has reached clinical phase 3. It is being assessed in combination with VX-661, VX-770, and/or VX-56. Although CFTR modulators have been shown to dominate the cystic fibrosis treatment market, there are still several challenges that need to be overcome. The currently available CFTR modulators drugs target the underlying cause of cystic fibrosis. However, some patients with rare CFTR mutations are still ineligible to receive currently marketed therapies. Therefore, the opportunity remains for developers to investigate CFTR modulators for less common mutations. In addition, resistance to these drugs is another challenge that needs to be overcome. The global CFTR modulator market is expected to surpass US$ 25 Billion by 2028. The increasing prevalence and increasing funding from several nonprofit organizations including, Cystic Fibrosis Foundation, Cystic Fibrosis WorldwideCystic Fibrosis Worldwide, South African Cystic Fibrosis Trust, and South African Cystic Fibrosis Association, will drive the market growth but also encourages the research and development activities in cystic fibrosis. These organizations are investing huge amounts of funds to find various CFTR modulators for cystic fibrosis and to support the research and developmental activities of prominent players. Further, the robust clinical pipeline of drugs that will gain approval during the forecast period will also boost the growth of the market. The report provides comprehensive details of the existing pure-play companies and new players entering the market with key drugs in research and development. Moreover, the report provides insights into the major challenges that are going to hamper the market growth during the forecast period. Additionally, the report provides information on the globally approved CFTR modulators along with their patent, price, dosage, and sales analysis till Q1 2022. Global CFTR Modulators Market Insights: Current, Regional, and Future Outlook 2028
Annual, Quarterly, and Regional Sales Insights On CFTR Modulators
CFTR Modulators Clinical Trials Insight By Country, Company, and Phase: > 30 Drugs 2. Global CFTR Modulators Mechanism of Action 6.3 Price & Dosage Insight
7.3 Price & Dosage Insight
8.3 Price & Dosage Insight
9.3 Price & Dosage Insight
9. Global CFTR Modulators Vaccine Pipeline Overview
10. Global CFTR Modulators Clinical Trials Insight
11. Marketed CFTR Modulators Clinical Insights
12. CFTR Modulator Drugs Market Dynamics
13.1 Favorable Parameters
14. Competitive Landscape
Southern Research Institute
For more information about this report visit https://www.researchandmarkets.com/r/eyz9tv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716